We cure intractable leg wounds with a replacement valve for veins.
Key people at InnoVein.
InnoVein was founded in 2015 by Al Chin (Founder) and Tom Kramer (Founder) and Austin Walker (Founder/CEO).
InnoVein is a medical device company that develops a first-in-class prosthetic valve implant specifically designed to replace malfunctioning valves in the femoral vein, addressing chronic venous insufficiency and intractable leg wounds. Their product uses biocompatible materials to ensure compatibility with human tissue, targeting a significant unmet medical need in vein disease treatment. The company serves vascular surgeons and patients suffering from venous valve failure, offering a novel solution where traditional treatments fall short. InnoVein has demonstrated growth momentum through successful fundraising, including backing from Y Combinator, the National Science Foundation, and venture capital firms, alongside recognition from Forbes and MIT[1][2][3].
Founded in 2015 in San Carlos, California, InnoVein was established by a team including S. Marlene Grenon, an associate professor of surgery and vascular surgeon with extensive experience in medical device innovation. The founders collectively have a strong track record, having invented and commercialized over 15 medical devices generating more than $3 billion in sales. The idea for InnoVein emerged from the clinical need to effectively treat venous insufficiency, a condition with limited therapeutic options. Early traction included securing prestigious awards and funding from notable institutions such as the National Science Foundation and venture capital investors, validating the technology and business model[1][2].
InnoVein is positioned at the intersection of medical device innovation and vascular health, riding the trend of minimally invasive, implantable solutions that improve chronic disease management. The timing is critical as the global burden of venous disease grows with aging populations and increasing prevalence of chronic wounds. Market forces such as rising healthcare costs and demand for effective outpatient treatments favor InnoVein’s approach. By introducing a novel valve replacement technology, InnoVein influences the vascular surgery ecosystem, potentially setting new standards for treating venous insufficiency and reducing complications like leg ulcers.
Looking ahead, InnoVein is poised to advance clinical trials and regulatory approvals to bring its valve replacement technology to broader markets. Trends shaping its journey include increasing adoption of implantable devices, personalized vascular therapies, and growing investment in medtech innovation. As InnoVein scales, it may expand its product portfolio and deepen collaborations with healthcare providers, further solidifying its role as a pioneer in venous disease treatment. Its success could redefine care paradigms for chronic venous insufficiency, improving patient outcomes and reducing healthcare burdens.
InnoVein was founded in 2015 by Al Chin (Founder) and Tom Kramer (Founder) and Austin Walker (Founder/CEO).
Key people at InnoVein.
